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MaBACKGROUND A total of 30% to 40% of patients with congestive heart failure eligible for cardiac resynchronization
therapy (CRT) either do not respond to conventional CRT or remain untreated due to an inability or impediment to
coronary sinus (CS) lead implantation. The WiSE-CRT system (EBR Systems, Sunnyvale, California) was developed to
address this at-risk patient population by performing biventricular pacing via a wireless left ventricular (LV) endocardial
pacing electrode.
OBJECTIVES The SELECT-LV (Safety and Performance of Electrodes implanted in the Left Ventricle) study is a
prospective multicenter non-randomized trial assessing the safety and performance of the WiSE-CRT system.
METHODS A total of 35 patients indicated for CRT who had “failed” conventional CRT underwent implantation of an LV
endocardial pacing electrode and a subcutaneous pulse generator. System performance, clinical efficacy, and safety
events were assessed out to 6 months post-implant.
RESULTS The procedure was successful in 97.1% (n ¼ 34) of attempted implants. The most common indications
for endocardial LV pacing were difficult CS anatomy (n ¼12), failure to respond to conventional CRT (n ¼ 10), and
a high CS pacing threshold or phrenic nerve capture (n ¼ 5). The primary performance endpoint, biventricular
pacing on the 12-lead electrocardiogram at 1 month, was achieved in 33 of 34 patients. A total of 28 patients
(84.8%) had improvement in the clinical composite score at 6 months, and 21 (66%) demonstrated a positive
echocardiographic CRT response ($5% absolute increase in LV ejection fraction). There were no pericardial
effusions, but serious procedure/device-related events occurred in 3 patients (8.6%) within 24 h, and 8 patients
(22.9%) between 24 h and 1 month.
CONCLUSIONS The SELECT-LV study demonstrates the clinical feasibility for the WiSE-CRT system, and provided
clinical benefits to a majority of patients within an otherwise “failed” CRT population. (Safety and Performance
of Electrodes Implanted in the Left Ventricle [SELECT-LV]; NCT01905670) (J Am Coll Cardiol 2017;69:2119–29)
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CS = coronary sinus
HF = heart failure
LV = left ventricle
LVEDV = left ventricular
end-diastolic volume
LVEF = left ventricular ejection
fraction
LVESV = left ventricular
end-systolic volume
RV = right ventricle
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2120C ardiac resynchronization therapy(CRT) can improve mortality andquality of life in patients with
depressed left ventricular ejection fraction
(LVEF), mild to severe heart failure (HF)
symptoms, and prolonged intraventricular
conduction time (1). Left ventricular (LV)
pacing via an implanted coronary sinus (CS)
lead is the first-line approach for achieving
CRT, but 30% to 40% of patients do not
respond to this conventional CRT (2).
Furthermore, an additional 8% to 10% of
eligible patients do not receive CRT due to
anatomical constraints, such as the absence
of appropriate CS targets, occlusion of theupper extremity venous system, phrenic nerve stimu-
lation, or high pacing threshold in areas of diffuse
scar (3,4). Prior approaches to achieve ventricular
resynchronization in patients who have either not
responded or failed CS implantation have included
surgical epicardial lead placement and transseptal
implantation of endocardial LV pacing leads (5). How-
ever, surgical epicardial lead placement is inherently
more invasive than the percutaneous approach, can
be especially challenging in patients with prior car-
diac surgery (pericardial adhesions), and is associated
with lower lead survival rates compared with transve-
nous leads (6). Although transseptal LV endocardial
stimulation may offer the benefits of providing more
physiological endocardial ventricular activation and
may even be less proarrhythmic compared with
epicardial LV pacing, this approach is limited by the
thromboembolic risk, need for lifelong systemic anti-
coagulation, and concern for mechanical effects on
the mitral valve.SEE PAGE 2130A system that performs endocardial LV stimulation
to achieve biventricular pacing, but does not require a
thoracotomy or systemic anticoagulation, would be
an attractive option for resynchronization therapy. In
this context, a novel wireless cardiac resynchroniza-
tion system (WiSE-CRT, EBR Systems, Sunnyvale,
California) was developed to pace the LV endocar-
dium with a small wireless pacing electrode. The
WiSE-CRT system provides wireless pacing by trans-
mitting acoustic (ultrasonic) energy from a pulse
generator transmitter, implanted subcutaneously
over the ribcage, to a receiver electrode implanted in
the LV. The WiSE-CRT System functions in conjunc-
tion with a coimplanted standard right ventricular
(RV) pacing system. Biventricular pacing is achieved
by sensing the RV pacing output of the coimplant,
followed by the system immediately transmittingacoustic energy to the electrode, thus achieving
nearly simultaneous pacing of the RV and LV.
The transmitter is a phased array ultrasound system
that focuses the acoustic energy on the electrode.
Herein, we present the 6-month outcomes of the
prospective multicenter clinical trial of the WiSE-CRT
system in the SELECT-LV (Safety and Performance of
Electrodes implanted in the Left Ventricle) study.
METHODS
STUDY DESIGN. The SELECT-LV study (NCT01905670)
was a multicenter (n ¼ 6 centers), prospective eval-
uation of the performance and safety of the WiSE-
CRT System in patients indicated for CRT who had
“failed” conventional CRT. Patients were eligible for
inclusion if they had a standard indication for CRT
and at least 1 of the following criteria: 1) “upgrades”:
CS lead implantation was not advisable/feasible due
to perceived risk (e.g., infection) or impediment (e.g.,
venous obstruction); 2) “untreated”: coronary sinus
lead implantation attempted but failed (e.g., difficult
CS anatomy, phrenic nerve capture); or 3) “non-
responders”: previously implanted conventional CRT
device with worsening of symptoms or worsening of
New York Heart Association (NYHA) functional class
after 6 months of CRT treatment. Patients were
excluded if they had nonambulatory (or unstable)
NYHA functional class IV HF symptoms, a contrain-
dication to heparin, a contraindication to long-term
anticoagulation and antiplatelet agents, stage 4 or 5
chronic kidney disease, major cardiac surgery within
the prior month, or noncardiac implanted electrical
stimulation devices. A serious adverse event was
defined as any event that led to death, serious dete-
rioration that resulted in a life-threatening illness or
injury, permanent impairment of body structure or
function, hospitalization or prolongation of existing
hospitalization, or a medical or surgical intervention.
ENDPOINTS. The primary performance endpoint was
evidence of biventricular pacing (on 12-lead electro-
cardiogram [ECG]) at 1 month. If the patient was not
pacemaker dependent, 12-lead ECGs were to be
obtained without pacing (intrinsic), during RV-only
pacing (by temporarily programming off the WiSE-
CRT system), and during biventricular pacing.
Biventricular capture was confirmed by comparing
the paced QRS morphology during biventricular
pacing with that during RV-only pacing. To meet this
endpoint, 2 performance criteria had to be met:
appropriate recognition of the sensed coimplant RV
pacing output (successful detection) and LV pacing
(successful capture). The primary performance
endpoint was based on the number of patients
FIGURE 1 Wireless Endocardial Left Ventricular Pacing
(A and B) Fluoroscopic images of the retrograde delivery sheath and pacing electrode engaged into the myocardium and following deployment. (C) Photograph and
dimensions of the pacing electrode. (D to F) Schematic representations of the implanted system and posteroanterior/lateral chest x-rays the day after implant. The
dashed line encircles the receiver/pacing electrode.
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2121who underwent implantation of the complete
system (n ¼ 34). The primary safety endpoints were
device-related complications at 2 time frames: from
implant to 24 h post-implant, and from 24 h to 30
days. The safety endpoints were based on intention
to treat (number of patients who underwent an
attempt at system implantation; n ¼ 35).
The secondary efficacy endpoints included: 1)
change in the HF clinical composite score (all-cause
mortality, HF hospitalization, NYHA functional
class, and patient global assessment) at 6 months;
and 2) change in echocardiographic left ventricular
end-systolic volume (LVESV), left ventricular end-
diastolic volume (LVEDV), and LVEF at 6 months
(3,7). The clinical composite score classifies the
patient as improved, unchanged, or worsened (8).
The global assessment score is a 7-point rating scale,
allowing for the evaluation of the patient’s own
perspective of overall health compared with a previ-
ous point in time (9). Positive responses to CRT
between baseline and at 6 months were defined as: 1)
reduction in LVESV by $15%; 2) reduction in LVEDV
by $10%; 3) improvement in LVEF by $5%; and 4)improvement of NYHA functional class by $1 (3). The
intrinsic and RV-paced QRS durations at baseline
(pre-CRT) were compared with the intrinsic,
RV-paced, and biventricular-paced QRS durations at
6 months; the delta QRS was defined as the intrinsic
QRS duration (ms) at baseline minus the
biventricular-paced QRS at 6 months. Secondary
safety endpoints included device-related complica-
tions between 1 and 6 months. All serious adverse
events were reviewed and adjudicated by an
independent clinical events committee. In-person
follow-up was performed at pre-discharge and at
1 week, 1 month, 2 months, and 6 months post-
implant.
SYSTEM DETAILS AND IMPLANTATION. As shown in
Figure 1, the WiSE-CRT system consists of 4 com-
ponents: 1) a 12-F steerable delivery catheter system
with an atraumatic inflatable polyester balloon at
the catheter tip; 2) an 8-F retractable delivery
catheter with a pre-mounted receiver electrode
(volume ¼ 0.05 ml); the electrode is an ultrasound
receiver and energy converter, and is implanted in
the LV via a transaortic retrograde approach; 3) a
TABLE 1 Demographics and Indications for LV Endocardial
Wireless Pacing (n ¼ 35)
Age, yrs 65.4  7.9
Male 29 (85)





NYHA functional class 2.6  0.6
LVEF, % 26.0  6.2
Hypertension 20 (57.1)
Diabetes 11 (31.4)
Chronic kidney disease 12 (34.3)
Coimplanted system
Single-chamber ICD 1 (2.9)
Dual-chamber PPM 1 (2.9)
Dual-chamber ICD 4 (11.4)
CRT-P 6 (17.1)
CRT-D 23 (65.75)
Indication for LV endocardial pacing implant
Difficult CS anatomy/access 12 (34.0)
Failure to respond to CRT 10 (29.0)
High CS threshold or phrenic nerve capture 5 (14.0)
CS lead dislodgement or lead failure 3 (9.0)
Prior infection or upper extremity occlusion 3 (9.0)
Other 2 (6.0)
Values are mean  SD or n (%).
BMI¼ body mass index; CRT¼ cardiac resynchronization therapy; CS¼ coronary
sinus; D ¼ defibrillator; ICD ¼ implantable cardioverter-defibrillator; LV ¼ left
ventricular; LVEF ¼ left ventricular ejection fraction; NYHA ¼ New York Heart
Association; P ¼ pacemaker; PPM ¼ permanent pacemaker.
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2122pulse generator that consists of an ultrasound
energy pulse transmitter and a battery, both of
which are implanted subcutaneously; and 4) the
programmer.
Implanting the WiSE system is a 2-step process.
Surgical subcutaneous implantation of the pulse
generator system is followed by catheter placement
of the LV pacing electrode. These 2 steps were per-
formed on consecutive days. To implant the pulse
generator, 2 surgical incisions are required: 1 for the
transmitter, and 1 for the battery. The battery pocket
is created at the midaxillary line. The location for the
transmitter requires an acoustic window, a lung- and
bone-free acoustic line of sight from the implant
location to the LV. This is most commonly located in
the 4th to 6th intercostal spaces lateral to the left
parasternal border and can be identified in pre-
procedure screening using transthoracic echocardi-
ography. In general, an acoustic window of 3 cm2 is
sufficient for nominal use of the system. After cut
down to the level of the intercostal muscle, an echo-
cardiogram probe in a sterile sleeve is used to further
assess the acoustic window prior to securing the
transmitter in the location. An accessory is secured to
the intercostal muscle using helical sutures, then the
transmitter is inserted into the accessory and su-
tured. Additionally, a subcutaneous channel between
the 2 pockets is created to pass and connect the cable
between the transmitter and the battery. The cable
length is 30 cm. As mentioned previously, the WiSE-
CRT system requires coimplantation of a commer-
cially available standard pacemaker, transvenous
defibrillator, or conventional CRT device to synchro-
nize biventricular pacing. Sensing electrodes on the
outside surface of the transmitter and battery enclo-
sures are used to detect RV pacing pulses from the
coimplanted device. Immediately after sensing the
RV pacing output, the WiSE-CRT system triggers an
ultrasound pulse that is received and transduced to
electrical energy to pace the LV. This occurs essen-
tially simultaneously to achieve biventricular pacing
(average time delay between RV pace sensing and LV
pacing is typically 3 to 5 ms).
For placement of the LV pacing electrode prior to
delivery sheath insertion, heparin is administered to
maintain an activated clotting time of 200 to 250 s.
The delivery sheath is advanced retrograde to the LV,
and then the delivery catheter with a pre-loaded
electrode is advanced until it is 5 to 10 mm proximal
to the tip of the delivery sheath. The cathode of the
electrode is connected through the delivery catheter
so that local electrogram signals can be monitored
and electrical pacing thresholds can be tested. By
advancing the electrode to the very distal end of thesheath, multiple endocardial pacing sites can be
tested prior to anchoring the electrode. Under fluo-
roscopic guidance, the pacing site evaluation includes
a combination of echocardiographic considerations,
electrical timing using local electrogram signals, and
pacing thresholds. The location, distance, and angle
of the electrode are tracked in real time during im-
plantation, as reported through the programmer by
the transmitter’s tracking algorithm. This confirms
that selected sites can be targeted relative to the
implant location of the transmitter. The transmitter
has a 2-dimensional phased array, providing angular
steering of the ultrasound beam along 2 orthogonal
directions. The transmitter uses this angular steering
to focus transmitted ultrasound at the location of the
electrode. If the angular location coincides with the
electrode, the electrode will produce an electrical
pulse that can be detected by the transmitter, indi-
cating the angular location of the electrode. Further-
more, the time lag between transmission of the
ultrasound impulse and detection of electrical output
is used to determine the distance between the
transmitter and electrode. The real-time information
TABLE 2 Clinical Efficacy Endpoints and Response to CRT
Parameter Baseline 6 Months Change p Value Response Definition
Response Rate
at 6 Months (%)
LVESV, ml (n ¼ 25) 183.8  62.9 157.0  75.7 26.8  45.1 0.007 $15% relative reduction 52
LVEDV, ml (n ¼ 25) 243.1  70.7 222.4  77.0 20.6  41.5 0.02 $10% relative reduction 40
LVEF, % (n ¼ 32) 25.9  6.4 33.0  10.3 þ7.1  8.0 <0.0001 $5% absolute increase 66
NYHA functional
class I/II/III/IV
3/24/73/0 24/67/3/6 þ0.8  0.8 $1 class improvement 67










Values are mean  SD or %.
LVEDV ¼ left ventricular end-diastolic volume; LVESV ¼ left ventricular end-systolic volume; other abbreviations as in Table 1.
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2123of the angular location as well as distance from
transmitter to electrode is presented to the user by a
graphic/data display during the site selection process.
Once an appropriate endocardial LV pacing site is
identified, the electrode is deployed/anchored into
the LV endocardium by advancing the catheter to
push the anchor of the electrode into the endocardial
surface.
Following implantation, patients were prescribed
aspirin 75 to 325 mg daily throughout the study
duration (6 months), and clopidogrel 75 mg daily for 3
months post-implant. For patients taking long-term
warfarin therapy for other indications (e.g., atrial
fibrillation, and so on), based on the center’s standard
practice, warfarin was permitted to be discontinued
2 to 3 days pre-procedure and reinitiated afterwards;
in these long-term warfarin patients, the addition of
antiplatelet agents was not required.
STATISTICAL ANALYSIS. Continuous variables are
expressed as mean  SD. We used a paired Student
t test to compare performance values between implant
(baseline) and follow-up intervals. A p value <0.05
was considered indicative of statistical significance.
Statistical calculations were performed by using SPSS
version 12.0 (SPSS Inc., Chicago, Illinois).
RESULTS
BASELINE DEMOGRAPHICS AND INDICATIONS FOR
ENDOCARDIAL LV PACING. The clinical character-
istics of the patients are shown in Table 1. Of the
patients enrolled in the clinical trial (n ¼ 39), 35
patients (89.7%) underwent the procedure. The
remaining patients (n ¼ 4) did not undergo a pro-
cedure because of either an inadequate acoustic
window (n ¼ 3) or patient withdrawal prior to the
planned implant procedure (n ¼ 1). The mean age ofthe cohort (n ¼ 35) was 65.4  7.9 years. The
prevalence of ischemic cardiomyopathy, non-
ischemic cardiomyopathy, and mixed cardiomyopa-
thy was 43% (n ¼ 15), 46% (n ¼ 16), and 11% (n ¼ 4),
respectively. More than one-half of the patients had
hypertension (57%; n ¼ 20), and approximately one-
third had diabetes (31%; n ¼ 11) and chronic kidney
disease (34%; n ¼ 12). Approximately two-thirds of
the patients had been receiving oral anticoagulation
with warfarin.
With regard to the standard coimplanted system,
the devices included biventricular implantable
cardioverter-defibrillators (n ¼ 23), biventricular
pacemakers (n ¼ 6), single/dual-chamber implantable
cardioverter-defibrillators (n ¼ 4), and dual-chamber
pacemaker (n ¼ 1). These coimplanted systems were
from 5 commercially available device companies,
including Medtronic (n ¼ 12), St. Jude Medical
(n ¼ 10), Boston Scientific (n ¼ 6), Biotronik (n ¼ 5),
and Sorin (n ¼ 1). The most common indications for
endocardial LV pacing were for difficult CS anatomy
(n ¼ 12; 34%), failure to respond to conventional CRT
(n ¼ 10; 29%), and a high CS pacing threshold or
phrenic nerve capture at low outputs (n ¼ 5; 14%).
Additional reasons included CS lead dislodgment or
lead failure (n ¼ 3; 9%), prior infection or upper
extremity venous occlusion (n ¼ 3; 9%), and other
(n ¼ 2; 6%). Completed follow-up was available for
34 patients at 1 month and for 33 patients at 6 months
(1 patient required system removal, as discussed in
the following text).
PROCEDURAL DETAILS. Of patients who underwent
an attempted implant (n ¼ 35), the procedure was
successful in 97.1% (n ¼ 34). One patient did not
have the electrode implanted due to ventricular
arrhythmia during the implantation procedure
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(A) Change in LV EF from baseline to 6 months. (B) Individual changes in LV EF from baseline to 6 months. (C) Change in LV EDV and LV ESV from baseline to 6 months.
(D) Change in QRS duration at baseline, 1 week, 2 weeks, 1 month, and 6 months. BiV ¼ biventricular; EDV ¼ end-diastolic volume; EF ¼ ejection fraction; ESV ¼ end
systolic volume; LV ¼ left ventricular; RV ¼ right ventricular.
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2124(see the following text). The mean procedure dura-
tions for implanting the pulse generator (i.e., trans-
mitter and battery) and pacing electrode, including
time for ACT to meet the 200- to 250-s target were 85
 35 min and 58  24 min, respectively. The optimal
acoustic window for pulse generator implant was
most commonly in the 6th intercostal space (60%; n ¼
21), followed by the 7th (17%; n ¼ 6), 5th (14%; n ¼ 5)
and 4th (9%; n ¼ 3) intercostal spaces. The mean
distance from the transmitter to the pacing electrode
was 8.5  1.6 cm.
PERFORMANCE, CLINICAL RESPONSE, AND
REMODELING ENDPOINTS. The primary perfor-
mance endpoint, biventricular pacing on the 12-lead
ECG, was achieved in 97.1% (n ¼ 33 of 34) ofpatients at 1 month and 93.9% (n ¼ 31 of 33) at
6 months. Biventricular pacing could not be demon-
strated in 2 patients at the 6-month follow-up due to
defective transmitters, which were subsequently
replaced. A majority of the patients (n ¼ 28 of 33;
84.8%) had an improvement in the clinical composite
score at 6 months, whereas a minority were either
unchanged (n ¼ 3; 9.1%) or worsened (n ¼ 2; 5.9%). As
shown in Table 2, two-thirds of the patients experi-
enced an improvement in NYHA functional class
by $1 (n ¼ 22; 66.7%) and an improvement in quality-
of-life scores (n ¼ 23; 69.7%). One patient was reho-
spitalized for HF (n ¼ 1; 3.0%) on 2 separate occasions.
As shown in Figure 2, there were significant
improvements between baseline and 6 months in
FIGURE 3 Representative Example of QRS Shortening With Left Ventricular Endocardial Wireless Pacing and Resynchronization Therapy
BV ¼ biventricular; INT ¼ intrinsic; RV ¼ right ventricular.
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2125LVEF (25.9  6.4% vs. 33.0  10.3%, respectively;
p < 0.001), LVEDV (243  71 ml vs. 224  77 ml,
respectively; p ¼ 0.02), and the LVESV (184  63 ml
vs. 157  76 ml, respectively; p ¼ 0.006). Using the
responder criteria for LVESV ($15% relative reduc-
tion), LVEDV ($10% relative reduction), and LVEF
($5% absolute increase), positive echocardiographic
responses to CRT were observed in 52% (n ¼ 13), 40%
(n ¼ 10), and 66% (n ¼ 21) of patients, respectively
(Table 2). As compared with the baseline QRS dura-
tion, there were significant reductions in the 6-month
intrinsic QRS (169.9  29.2 ms vs. 142.6  27.3 ms,
p < 0.001) but not in RV-paced QRS (187.2  30.3 ms
vs. 182.0  32.2 ms, p ¼ 0.21) durations. In patients
where intrinsic QRS data was available at baseline
and at 6 months (n ¼ 20), there were significant
reductions in the intrinsic QRS duration (Figure 2D).An illustrative example from a patient implanted with
the WiSE-CRT system, demonstrating a narrower QRS
compared with RV-paced and intrinsic rhythm, and
QRS shortening over time (from 1 to 6 months) is
shown in Figure 3.
SAFETY. As shown in Table 3, the primary safety
endpoint of serious procedure- or device-related
events occurred in 3 patients (8.6%) within the first
24 h. One patient developed ventricular fibrillation
during the electrode implant procedure (following
contact of the delivery catheter with the LV endo-
cardium), which required prolonged resuscitation
(37 min). This patient died 4 days later due to
complications from the cardiac arrest. In 1 patient, the
electrode embolized to the left tibial artery during an
exchange of the dilator and catheter, prior to intro-
duction of the sheath into the LV. Following
TABLE 3 Device- or Procedure-Related Adverse Events (n ¼ 35)
<24 h 3 (8.6%)
VF during catheter contact with LV endocardium 1
Electrode embolization to lower extremity 1
Femoral artery fistula (required surgical repair) 1
24 h to 1 month 8 (22.3)
Acute CVA (AF noncompliant with anticoagulation) 1
Femoral pseudoaneurysm 2
Pocket hematoma (generator) 1
Suspected infection (generator site) 3
Death (following VF during initial implant procedure) 1
1 to 6 months 3 (8.6)
Defective transmitter circuitry 3
Values are n (%) or n.
AF ¼ atrial fibrillation; CVA ¼ cerebrovascular accident; LV ¼ left ventricular;









CRT ¼ cardiac resync
MIRACLE ¼ Multicen
Multicenter InSync R
to CRT; REVERSE ¼
dysfunction; SELECT
Left Ventricle.
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2126angiography and surgical consultation, it was deemed
not necessary to retrieve the embolized electrode
because of the absence of angiographic occlusion or
clinical symptoms. Another electrode was then placed
in the LV with acceptable pacing parameters. The
third patient developed a femoral artery fistula that
required surgical repair.
The other primary safety endpoint of serious
procedure- or device-related events between 24 h andComposite Score in SELECT-LV Compared With
ubjects
Clinical Composite Score Response (% Patients) with CRT
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-LV ¼ Safety and Performance of Electrodes implanted in the1 month occurred in 8 patients (22.9%) (Table 3). As
mentioned previously, 1 patient died 4 days following
catheter-induced VF. One patient with AF developed
a stroke (basilar artery) 3 days after the implant, in
the context of warfarin noncompliance (international
normalized ratio ¼ 1.1 at time of stroke). This patient
recovered without residual neurological deficit. There
were 3 suspected or proven infections: 1 patient did
not require additional treatment, but the patient was
hospitalized for 1 day of observation; 1 patient was
treated with oral and IV antibiotics for suspected
infection at the battery pocket surgical site; and
1 patient required removal of the WiSE-CRT system
due to draining fluid from the transmitter pocket.
There were 2 femoral artery pseudoaneurysms, 1 of
which was repaired percutaneously, and the other
required surgical correction.
DISCUSSION
In a population of failed conventional CRT patients,
the SELECT-LV trial demonstrated that cardiac
resynchronization with endocardial LV stimulation
via a novel leadless pacing electrode was technically
feasible and efficacious. We demonstrated: 1) a high
implant success rate (97%); 2) improvements in the
HF clinical composite score in 85% of patients; and 3)
a positive echocardiographic CRT response (reduction
in LVESV $15%) in 52% of patients at 6 months. As
shown in Figure 4, these clinical outcomes compared
quite favorably to the clinical and structural im-
provements observed in conventional CRT trials. For
example, in the intervention arm of the PROSPECT
(Predictors of Response to CRT) trial, the clinical
composite score improved in 69% of patients and
LVESV decreased by $15% in 56% of patients (3,10,11).
Additionally, in the SELECT-LV trial, there was also
evidence of resynchronization-induced electrical
remodeling, which is believed to be associated with
better clinical and structural response (12). In patients
where intrinsic QRS data was available at baseline
and at 6 months, there were significant reductions in
the intrinsic QRS duration: 55% (11 of 20) patients
were noted to have a shortening of the intrinsic QRS
duration by at least 20 ms (Central Illustration).
Overall, the biventricular paced QRS at 6 months was
51 ms shorter than the RV-paced QRS at baseline and
36 ms shorter than the intrinsic QRS at baseline.
These data are particularly compelling given that the
enrolled cohort were largely patients who failed or
were poor candidates for conventional CRT.
To date, there have been various strategies utilized
to offer CRT to patients who are not candidates for
conventional coronary sinus pacing. Perhaps the most
CENTRAL ILLUSTRATION Wireless Left Ventricular Endocardial Pacing
Reddy, V.Y. et al. J Am Coll Cardiol. 2017;69(17):2119–29.
The WiSE-CRT system is shown. The pacing system consists of a receiver electrode and an ultrasound transmitter, which is powered by a battery. The transmitter
detects the right ventricular pacing pulse from a co-implanted pacing system. The transmitter then transmits ultrasound energy to a receiver electrode, which is
implanted in the left ventricular endocardium. The receiver electrode converts the ultrasound energy into electrical pacing impulses. The cumulative effects, including
clinical response, structural remodeling, and electrical remodeling are depicted. ESV ¼ end systolic volume; ICD ¼ implantable cardioverter-defibrillator; LV ¼ left
ventricular; RV ¼ right ventricle.
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2127commonly employed approach is surgical placement
of an epicardial lead. However, this procedure is
limited by need for a thoracotomy, poor long-term
performance of epicardial pacing leads, and limited
access to optimal LV pacing sites (basal). An alternative
technique for achieving nonconventional resynchro-
nization therapy is transseptal (either interatrial or
interventricular) implantation of a transvenous pacing
lead. However, this approach can be associated with a
concerning high thromboembolic risk (10%) despite a
relatively high international normalized ratio goal
(2.5 to 4.5), a requirement for lifelong anticoagulationtherapy, and the potential for long-term negative ef-
fects of these conventional pacing leads on adjacent
structures (e.g., the mitral valve) (13). Nonetheless, as
demonstrated in the ALSYNC (ALternate Site Cardiac
ResYNChronization) study, which evaluated atrial
transseptal LV pacing, there are some important
potential benefits of LV endocardial pacing. Nearly
one-half (42%) of the ALSYNC trial patients were
nonresponders with conventional CRT, but converted
to CRT responders with transseptal endocardial LV
pacing; 55% of patients had significant ($15%) re-
ductions in LV end-systolic volume, and 59% of
Reddy et al. J A C C V O L . 6 9 , N O . 1 7 , 2 0 1 7
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2128patients achieved an improvement of at least 1 NYHA
functional class at 6 months (14). Given these
intriguing data of several potential advantages of
endocardial LV pacing over conventional epicardial
LV pacing, including faster ventricular activation and
superior hemodynamic performance, it is reasonable
to postulate that endocardial LV pacing could even-
tually become a first-line option in patients requiring
CRT—if the safety profile and implantation techniques
were in line with current standards.
An earlier version of the wireless LV endocardial
pacing system was limited by prohibitive safety
concerns. Specifically, the WiSE-CRT study was
stopped after only 17 patients because of a very high
incidence of pericardial tamponade (n ¼ 3; 18%),
which was fatal in 1 patient (15). The delivery system
used in the SELECT-LV trial was redesigned such
that the distal portion of the delivery sheath was
equipped with a balloon to facilitate atraumatic
engagement with the LV endocardium; indeed, there
were no pericardial effusions in the SELECT-LV
study (16). However, it should be noted that there
was 1 occurrence of ventricular fibrillation due to de-
livery catheter-induced ventricular ectopy (prior to
extrusion of the pacing electrode), which resulted in a
prolonged resuscitation and eventual death. Further-
more, there were 2 confirmed infections related to the
subcutaneous pulse generator. Although 1 was suc-
cessfully treated with antibiotics, the other required
system removal. Future planned enhancements such
as a smaller pulse generator are in development; this
may reduce the risk of infection and hematoma
formation.
STUDY LIMITATIONS. Although prospective, this was
a nonrandomized trial without a control cohort, so
robust conclusions cannot be drawn as to its compar-
ative efficacy. Clinical response measures are subject
to the placebo effect, and the absence of a core echo-
cardiography reading laboratory introduces the pos-
sibility of reader bias. Although various clinical, ECG,
and cardiac function characteristics have been shown
to predict CRT response, these various methods to
assess CRT response often do not yield similar
response rates (17–19). Nevertheless, there was
objective evidence of resynchronization response, as
demonstrated by the improvements in both echocar-
diographic and electrical measures of reverse remod-
eling. The WiSE-CRT system requires 2 chest wall
incisions, which can predispose to infectious compli-
cations, as well as retrograde arterial access, which can
result in vascular complications. Fortunately, the
absence of a direct conduit to the endocardium reduces
the likelihood of resulting endocarditis. Torturousarterial access could potentially complicate the
implant success rate, although a high implantation
success rate was observed in this trial. This study did
not account for the potential effect of newer quad-
ripolar coronary sinus pacing leads, which have been
shown to be effective (comparedwith bipolar coronary
sinus leads) for managing complications such as
phrenic nerve stimulation and high pacing thresholds,
and reduce the need for lead repositioning (20).
Although only seen in 1 patient (who was in chronic AF
and subtherapeutic on warfarin), thromboembolic
complications do remain a concern with a foreign
body (albeit small) within the LV. The optimal
anticoagulation strategy (antiplatelets vs. systemic
oral anticoagulation) remains to be determined.
Endocardial scar and inadequate acoustic windows
could negatively affect the performance and battery
life of the system. In this study, 7.7% of the patients
enrolled (3 of 39) in the study did not have an adequate
acoustic window, and therefore did not undergo an
attempt at system implant. Although the final location
of the wireless pacing electrode in the LV was typically
the lateral wall or midbasal posterolateral, the primary
objective in this study was to find a suitable location as
determined by pacing threshold, electrogram, and an
adequate acoustic window, and the methods of the
study did not include optimal site selection strategies
in the LV or emphasize concurrence of “clinical” site
selection with acoustic windows. The need for and
ability to retrieve a long-term implanted pacing elec-
trode remains untested.Many of these concernswill be
addressed in an upcoming larger, multicenter Food
and Drug Administration trial to start in the United
States and Europe in late 2016.
CONCLUSIONS
The SELECT-LV study has demonstrated the clinical
feasibility for the WiSE-CRT system. This approach
provided clinical benefits in patients with a standard
indication for CRT who met the criteria of upgrade,
untreated, or nonresponder, a “failed” CRT popula-
tion. Additional studies within post-market surveil-
lance registries or randomized controlled trials are
needed to understand long-term outcomes, compare
additional outcomes, and explore different tech-
niques for selecting the optimal endocardial pacing
site.
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PERSPECTIVES
COMPETENCY IN MEDICAL KNOWLEDGE: CRT re-
duces mortality and HF hospitalization and improves
quality of life in patients with HF, reduced LVEF and left
bundle-branch block, or a high burden of RV pacing.
When biventricular pacing is indicated but cannot be
provided because of difficulty establishing stable pacing
from the coronary sinus, resynchronization can be
achieved with a leadless LV endocardial pacemaker.
TRANSLATIONAL OUTLOOK: Larger trials are needed
to confirm the safety, efficacy, and long-term clinical
benefit of wireless LV endocardial pacing.
J A C C V O L . 6 9 , N O . 1 7 , 2 0 1 7 Reddy et al.
M A Y 2 , 2 0 1 7 : 2 1 1 9 – 2 9 Wireless LV Endocardial Pacing
2129RE F E RENCE S1. Moss AJ, Hall WJ, Cannom DS, et al. Cardiac-
resynchronization therapy for the prevention of
heart-failure events. N Engl J Med 2009;361:
1329–38.
2. McAlister FA, Ezekowitz J, Hooton N, et al.
Cardiac resynchronization therapy for patients
with left ventricular systolic dysfunction: a sys-
tematic review. JAMA 2007;297:2502–14.
3. Chung ES, Leon AR, Tavazzi L, et al. Results of
the Predictors of Response to CRT (PROSPECT)
trial. Circulation 2008;117:2608–16.
4. Leon AR, Abraham WT, Curtis AB, et al. Safety of
transvenous cardiac resynchronization system im-
plantation in patients with chronic heart failure:
combined results of over 2,000 patients from a
multicenter study program. J Am Coll Cardiol 2005;
46:2348–56.
5. Mihalcz A, Kassai I, Geller L, Szili-Torok T.
Alternative techniques for left ventricular pacing
in cardiac resynchronization therapy. Pacing Clin
Electrophysiol 2014;37:255–61.
6. Lau EW. Achieving permanent left ventricular
pacing-options and choice. Pacing Clin Electro-
physiol 2009;32:1466–77.
7. Abraham WT, Fisher WG, Smith AL, et al.
Cardiac resynchronization in chronic heart failure.
N Engl J Med 2002;346:1845–53.
8. Packer M. Proposal for a new clinical end point
to evaluate the efficacy of drugs and devices in the
treatment of chronic heart failure. J Card Fail
2001;7:176–82.
9. Auger D, Ducharme A, Harel F, Thibault B,
O’Meara E. Patient assessment for cardiacresynchronization therapy: Past, present and
future of imaging techniques. Can J Cardiol 2010;
26:27–34.
10. Young JB, Abraham WT, Smith AL, et al.
Combined cardiac resynchronization and implant-
able cardioversion defibrillation in advanced
chronic heart failure: the MIRACLE ICD Trial. JAMA
2003;289:2685–94.
11. Gold MR, Daubert C, Abraham WT, et al. The
effect of reverse remodeling on long-term survival
in mildly symptomatic patients with heart failure
receiving cardiac resynchronization therapy:
results of the REVERSE study. Heart Rhythm 2015;
12:524–30.
12. Bonakdar HR, Jorat MV, Fazelifar AF, et al.
Prediction of response to cardiac resynchroniza-
tion therapy using simple electrocardiographic and
echocardiographic tools. Europace 2009;11:
1330–7.
13. Rademakers LM, van Gelder BM, Scheffer MG,
Bracke FA. Mid-term follow up of thromboembolic
complications in left ventricular endocardial
cardiac resynchronization therapy. Heart Rhythm
2014;11:609–13.
14. Morgan JM, Biffi M, Geller L, et al. ALter-
nate Site Cardiac ResYNChronization (ALSYNC):
a prospective and multicentre study of left
ventricular endocardial pacing for cardiac
resynchronization therapy. Eur Heart J 2016;37:
2118–27.
15. Auricchio A, Delnoy PP, Butter C, et al.
Feasibility, safety, and short-term outcome of
leadless ultrasound-based endocardial leftventricular resynchronization in heart failure
patients: results of the wireless stimulation
endocardially for CRT (WiSE-CRT) study. Euro-
pace 2014;16:681–8.
16. Miller MA, Neuzil P, Dukkipati SR, Reddy VY.
Leadless cardiac pacemakers: back to the future.
J Am Coll Cardiol 2015;66:1179–89.
17. Hawkins NM, Petrie MC, Burgess MI,
McMurray JJ. Selecting patients for cardiac
resynchronization therapy: the fallacy of echo-
cardiographic dyssynchrony. J Am Coll Cardiol
2009;53:1944–59.
18. Anker SD, Schroeder S, Atar D, et al. Tradi-
tional and new composite endpoints in heart
failure clinical trials: facilitating comprehensive
efficacy assessments and improving trial effi-
ciency. Eur J Heart Fail 2016;18:482–9.
19. Daubert JC, Saxon L, Adamson PB, et al.
2012 EHRA/HRS expert consensus statement on
cardiac resynchronization therapy in heart fail-
ure: implant and follow-up recommendations
and management. Heart Rhythm 2012;9:
1524–76.
20. Forleo GB, Della Rocca DG, Papavasileiou LP,
Molfetta AD, Santini L, Romeo F. Left ventricular
pacing with a new quadripolar transvenous lead
for CRT: early results of a prospective comparison
with conventional implant outcomes. Heart
Rhythm 2011;8:31–7.KEY WORDS cardiac resynchronization
therapy, leadless pacemaker
